ConductScience.org, home

Comparison · NCT01050647-ad63ebcf

17-hydroxyprogesterone Caproate vs Castor Oil Injections: Number of Participants With Neonatal Necrotizing Enterocolitis

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 17-hydroxyprogesterone Caproate vs Castor Oil Injections: Number of Participants With Neonatal Necrotizing Enterocolitis. Trial comparisons, record NCT01050647-ad63ebcf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01050647-ad63ebcf

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.20.05670.51wilson
Risk in group 20.09090.01620.377wilson
Risk difference, group 1 minus group 20.109-0.2110.428newcombe hybrid score
Risk ratio, group 1 over group 22.20.23420.7log
Odds ratio, group 1 over group 22.50.19132.8log
Number needed to treat, for one more participant with the outcome on 17-hydroxyprogesterone Caproate than on Castor Oil Injections9.17from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 117-hydroxyprogesterone CaproateWeekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation~17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.210OG000
Group 2Castor Oil InjectionsWeekly injections of Caster Oil (placebo)~Caster Oil injections: Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.111OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Neonatal Necrotizing Enterocolitis
Description
Time frame
From delivery to neonatal discharge, assessed up to 2 months
Population

Source ClinicalTrials.gov

Trial

Title
Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
NCT number
NCT01050647
Phases
PHASE1, PHASE2
Conditions
Pregnancy Complications
Interventions
17-Hydroxyprogesterone Caproate, Caster Oil injections
Lead sponsor
Stanford University
Results first posted
2018-04-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01050647-ad63ebcf